Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘ASH 2015 CAR T cells’

ASH 2014 San FranciscoThe 2015 annual meeting of the American Society of Hematology (ASH) (Twitter #ASH15) in Orlando has a bumper crop of interesting data.

ASH is one of the my favourite meetings on our conference calendar. I’ve been attending for many years, starting with when I was a commercial account manager for Hematology, Immunology, Transplantation and Oncology in the UK, then at Novartis in the US, when I was part of the team that brought Gleevec to market.

Hematologists make for an interesting group of people to talk to!  They are very focused on the science behind a disease and how translational research can move the needle forward and generate better outcomes for their patients.

As part of our continuing preview of #ASH15, I’ve taken a quick look at the late-breaking abstracts that were released today. We will have more in-depth coverage after we’ve heard the data presented in the 7.30-9.30 am session on Tuesday December 8.

Subscribers can login to read more or you can sign up in the box below.

If you’re not already a subscriber, but what to know “What’s hot at ASH15?” then you should purchase access.  Additional ASH previews are already planned.  By the time you’ve read them, you should “hit the ground running” in Orlando.

As Warren Buffett famously said, “Price is what you pay. Value is what you get.” I couldnt agree more. We have subscribers who just purchase our ASH coverage every year, so do check it out if you haven’t done so already.

That’s the $64K question we all want to know, and what’s more is gene editing necessary when it comes to creating an “off-the-shelf” T cell therapy, which instead of modifying a patient’s own T cells (autologous), uses cells from a healthy donor (allogeneic)?

We were really curious too, and sought out one of the world’s leading experts for their opinion on this very issue.

Subscribers can login to read more, along with our analysis of the potential impact of this latest news on CAR T cell therapies.

Downtown Disney Orlando

Downtown Disney, Orlando

It’s an exciting week for cancer drug development with the AACR-NCI-EORTC molecular targets meeting in Boston (Twitter: #Targets15) and the 2015 annual meeting of the Society for Immunotherapy of Cancer (SITC) at National Harbor, MD (Twitter: #SITC2015)

However, today’s news is the much anticipated release of the abstracts (apart from the late breakers and press program) for the 2015 American Society of Hematology (ASH) annual meeting (Twitter: #ASH15) that takes place in Orlando from December 5-8th. We’ll at the meeting for the blog.

There is so much great science at ASH, it’s really hard to do it justice – we’ve been known to spend most of the meeting in the poster halls…and until you see the data it’s impossible to provide detailed commentary or analysis.

However, there’s so much interest in the abstracts that for the benefit of our subs, I’ve highlighted several that caught my attention in what is a fast, real-time, top-line review while at SITC this morning.

This initial review covers two hot topics in cancer immunotherapy – CAR T cells and Checkpoint inhibitors.

Subscribers can login below or you can purchase access if you’d like to read our SITC and ASH conference coverage.

error: Content is protected !!